KR960034200A - 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체 - Google Patents

항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체 Download PDF

Info

Publication number
KR960034200A
KR960034200A KR1019960005354A KR19960005354A KR960034200A KR 960034200 A KR960034200 A KR 960034200A KR 1019960005354 A KR1019960005354 A KR 1019960005354A KR 19960005354 A KR19960005354 A KR 19960005354A KR 960034200 A KR960034200 A KR 960034200A
Authority
KR
South Korea
Prior art keywords
compound
vascular headache
administered
hydrogen
effective amount
Prior art date
Application number
KR1019960005354A
Other languages
English (en)
Inventor
알. 크렌쇼 로니
에이치. 뤼디거 에드워드
더블유. 스미쓰 데이비드
솔로몬 카롤라
예비치 조셉
Original Assignee
니콜라스 피 · 말라테스티닉
브리스톨-마이어즈 스퀴브 컴페니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니콜라스 피 · 말라테스티닉, 브리스톨-마이어즈 스퀴브 컴페니 filed Critical 니콜라스 피 · 말라테스티닉
Publication of KR960034200A publication Critical patent/KR960034200A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

식(Ⅰ)의 인돌린알킬피페라진일 피리딘 및 피리미딘의 일련의 신규 5-(3,4-디아미노-1,2,5-티아디아졸 S-옥사이드) 유도체가 혈관성 두통의 완화에 사용되는 것이 목적이다.
식 (Ⅰ)에서 X는 S, SO 및 SO2중에서 선택된다.

Description

항편두통의 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 식 (Ⅰ)의 화합물 또는 약리학적으로 허용되는 산부가염 및/또는 그의 용매화물:
    상기 식에서 R1은 수소, 할로겐, 저급 알킬 및 저급 알콕시 중에서 선택되고; R2,R3및 R5는 각각 수소 및 저급 알킬 중에서 선택되고; R4는 저급 알콕시; R5는아미노, 저급 알킬아미노, 디-저급 알킬아미노 및 저급 알콕시이며; X는 S, So 및 SO2중에서 선택되고, Y 및 Z는 각각 Y 및 Z가 모두 다 동시에 CH일 수 없다는 조건하에 N 및 CH중에서 선택되며; m은 제로 및 1~3의 정수 중에서 선택되고; n은 1~5 정수 중에서 선택된다.
  2. 제1항에 있어서, Y 및 Z가 N인 화합물.
  3. 제1항에 있어서, X가 SO인 화합물.
  4. 제3항에 있어서, R1,R2,R3및 R5가 수소인 화합물.
  5. 제3항에 있어서, m이 제로이고 n이 3인 화합물.
  6. 제3항에 있어서, R4가 메톡시인 화합물.
  7. 제3항에 있어서, R1,R2,R3및 R5가 수소이고, R4가 메톡시이고; Y 및 Z가 N이고; m이 제로이며 n이 3인 화합물.
  8. 제7항에 있어서, R5가 아미노 메틸아미노, 디메틸아미노, 및 메톡시인 화합물 중에서 선택된 화합물.
  9. 혈관성 두통에 걸린 사람에게 제1항의 화합물의 치료 유효량을 투여하는 혈관성 두통의 치료방법.
  10. 혈관성 두통에 걸린 사람에게 제3항의 화합물의 치료 유효량을 투여하는 혈관성 두통의 치료방법.
  11. 초기의 혈관성 두통에 걸린 사람에게 제1항의 화합물의 예방 유효량을 투여하는 혈관성 두통의 중지방법.
  12. 초기의 혈관성 두통에 걸린 사람에게 제3항의 화합물의 예방 유효량을 투여하는 혈관성 두통의 중지방법.
  13. 혈관성 두통의 위험이 있거나 혈관성 두통에 걸린 사람에게 전신 투여에 적합한 단위 투여랑 형태의 약제 조성물로서, 조성물이 약제 부형제와 제1항의 화합물 약 1~500㎎로 이루어진 약제 조성물.
  14. 혈관성 두통의 위험이 있거나 혈관성 두통에 걸린 사람에게 전신 투여에 적합한 단위 투여랑 형태의 약제 조성물로서, 조성물이 약제 부형제와 제3항의 화합물 약 1~500㎎로 이루어진 약제 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960005354A 1995-03-02 1996-02-29 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체 KR960034200A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/396,825 1995-03-02
US08/396,825 US5618816A (en) 1995-03-02 1995-03-02 Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridnyl and pyrimidinylpiperazines

Publications (1)

Publication Number Publication Date
KR960034200A true KR960034200A (ko) 1996-10-22

Family

ID=23568771

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960005354A KR960034200A (ko) 1995-03-02 1996-02-29 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체

Country Status (17)

Country Link
US (1) US5618816A (ko)
EP (1) EP0729958A2 (ko)
JP (1) JPH08253479A (ko)
KR (1) KR960034200A (ko)
CN (1) CN1063177C (ko)
AR (1) AR002281A1 (ko)
AU (1) AU707770B2 (ko)
CA (1) CA2169804A1 (ko)
CZ (1) CZ46896A3 (ko)
HU (1) HUP9600498A3 (ko)
IL (1) IL117224A (ko)
NO (1) NO305248B1 (ko)
NZ (1) NZ286090A (ko)
PL (1) PL313022A1 (ko)
RU (1) RU2165420C2 (ko)
TW (1) TW331558B (ko)
ZA (1) ZA961392B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU694226B2 (en) * 1994-05-19 1998-07-16 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives ofindol-3-ylalkyl as 5-HT1D-alpha agonists
GB9415575D0 (en) * 1994-08-02 1994-09-21 Merck Sharp & Dohme Therapeutic agents
GB9501865D0 (en) * 1995-01-31 1995-03-22 Merck Sharp & Dohme Therapeutic agents
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
JP4616009B2 (ja) * 2002-12-26 2011-01-19 ポーゼン インコーポレイテッド ＮＳＡＩＤｓおよびトリプタンを含有する多層剤型
US20070184109A1 (en) * 2003-06-06 2007-08-09 Floyd Alison G Compositions comprising triptans and nsaids
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
WO2016192657A1 (en) 2015-06-03 2016-12-08 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3468882A (en) * 1966-10-07 1969-09-23 Sterling Drug Inc Phenylhydrazone derivatives as intermediates for preparing indoles
NL189197C (nl) * 1979-09-04 1993-02-01 Bristol Myers Squibb Co 3,4-digesubstitueerde-1,2,5-thiadiazool-1-oxiden en 1,1-dioxiden, bereiding daarvan alsmede farmaceutische preparaten.
US4600779A (en) * 1982-03-29 1986-07-15 Bristol-Myers Company Substituted 3,4-diamino-1,2,5-thiadiazoles having histamine H2 -receptor antagonist activity
IT1170387B (it) * 1982-06-07 1987-06-03 Glaxo Group Ltd Composti eterociclici, procedimento per prepararli e composizioni farmaceutiche che li contengono
US4440933A (en) * 1983-03-16 1984-04-03 Bristol-Myers Company Process for preparing 1,2,5-thiadiazoles
GB2162522B (en) * 1984-08-01 1988-02-24 Glaxo Group Ltd An indole derivative
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
FR2635104B1 (fr) * 1988-08-03 1992-04-30 Synthelabo Derives d'indolone, leur preparation et leur application en therapeutique
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
US5077293A (en) * 1990-06-29 1991-12-31 Bristol-Myers Squibb Co. 1-indolyalkyl-4-(alkoxypyrimidinyl)piperazines
CA2043709C (en) * 1990-06-29 2002-01-22 David W. Smith Antimigraine alkoxypyrimidine derivatives
DE4101686A1 (de) * 1991-01-22 1992-07-23 Merck Patent Gmbh Indolderivate
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
CA2130078A1 (en) * 1993-09-16 1995-03-17 Jonas A. Gylys Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
GB9410031D0 (en) * 1994-05-19 1994-07-06 Merck Sharp & Dohme Therapeutic agents
AU694226B2 (en) * 1994-05-19 1998-07-16 Merck Sharp & Dohme Limited Piperazine, piperidine and tetrahydropyridine derivatives ofindol-3-ylalkyl as 5-HT1D-alpha agonists
GB9415575D0 (en) * 1994-08-02 1994-09-21 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
CN1138042A (zh) 1996-12-18
EP0729958A3 (ko) 1996-10-02
JPH08253479A (ja) 1996-10-01
NO960699L (no) 1996-09-03
IL117224A (en) 2000-06-29
CA2169804A1 (en) 1996-09-03
ZA961392B (en) 1997-08-21
IL117224A0 (en) 1996-06-18
TW331558B (en) 1998-05-11
NZ286090A (en) 1997-12-19
HUP9600498A3 (en) 1998-10-28
AU707770B2 (en) 1999-07-22
EP0729958A2 (en) 1996-09-04
CN1063177C (zh) 2001-03-14
RU2165420C2 (ru) 2001-04-20
CZ46896A3 (en) 1996-09-11
NO305248B1 (no) 1999-04-26
PL313022A1 (en) 1996-09-16
HU9600498D0 (en) 1996-04-29
HUP9600498A2 (en) 1997-10-28
NO960699D0 (no) 1996-02-22
US5618816A (en) 1997-04-08
AR002281A1 (es) 1998-03-11
AU4581996A (en) 1996-09-12

Similar Documents

Publication Publication Date Title
KR930003912A (ko) 울혈성 심장 마비 치료법
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
CA2039197A1 (en) Pharmaceutic Formulation for the Treatment of Alcoholism
EP1475114A3 (en) Injection system suitable for the administration of semisolid, sustained-release pharmaceutical compositions of gelable peptide salts
DE68921760D1 (de) Behandlung von beschädigtem knochenmark und dosierungseinheiten dafür.
FI872864A0 (fi) Menetelmä farmaseuttisesti aktiivisten bentsimidatsolijohdannaisten valmistamiseksi
KR950016745A (ko) 생리증상의 치료방법 및 이를 위한 조성물
DE69415445D1 (de) Zytotoxische Stilben-Derivate und diese enthaltende pharmazeutische Zusammensetzungen
KR890016966A (ko) 신규 항바이러스제
KR960034200A (ko) 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체
KR970704710A (ko) 트리아졸 화합물 및 도파민 D₃리간드로서의 그의 용도(Triazole Compounds and Their Use as Dopamine-D₃-Ligands)
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
KR970707108A (ko) 항염증제로 유용한, 복소환부를 갖는 디-t-부틸페놀 화합물(DI-TERT-BUTYLPHENOL COMPOUNDS WITH HETEROCYCLIC MOIETY, USEFUL AS ANTI-INFLAMMATORY AGENTS)
KR970025615A (ko) 암 전이 억제제
MY120318A (en) Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses.
DE69312567D1 (de) 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel
KR920019350A (ko) 자기면역질환요법을 위한 약제조성물
ATE55248T1 (de) Arzneimittelkombination.
RU96103685A (ru) 1,2,5-тиадиазольные производные индолилалкил-пиридинил- и пиримидинил-пиперазинов, способ лечения или предотвращения развития сосудистой головной боли и фармацевтическая композиция
ATE40127T1 (de) 1,5-benzothiazepinderivate, verfahren zu ihrer herstellung und arzneimittel.
KR900012925A (ko) 인돌 유도체
DE3870167D1 (de) N-(vinblastinoyl-23)-derivate von 1-aminomethylposphonsaeure, verfahren zu ihrer herstellung und sie enthaltende arzneimittel.
KR880004810A (ko) 소화성 궤양 치료제
ATE716T1 (de) Cytostatisch wirkende arzneimittel bzw. pharmazeutische zubereitungen.
KR960700711A (ko) 뇌혈관성 질환의 치료 또는 예방용 약제(Medicament for treating or preventing cerebrovascular diseases)

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application